Similar to other repurposed compounds previously evaluated for AxD, such as curcumin and ceftriaxone (Bachetti et al., 2010b; Bachetti et al., 2012), the molecules taken into consideration in the present work have displayed a variable range of beneficial effects, including the induction of HSP27 and alphaB-crystallin cellular expression, reduction of cellular GFAP levels by interfering with its gene expression, and elimination of the p. R239C mutant protein (Figure 8). The gene discussed is CRYAB; the disease is Alexander disease.